Biolife Solutions Stock Cash And Equivalents

BLFS Stock

USD 26.01 0.62 2.44%

BioLife Solutions fundamentals help investors to digest information that contributes to BioLife Solutions' financial success or failures. It also enables traders to predict the movement of BioLife Stock. The fundamental analysis module provides a way to measure BioLife Solutions' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to BioLife Solutions stock.

Other Current Liab Total Assets

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

BioLife Solutions Company Cash And Equivalents Analysis

BioLife Solutions' Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.

Cash

Bank Deposits

+

Liquidities

More About Cash And Equivalents | All Equity Analysis

Current BioLife Solutions Cash And Equivalents

46.55 M

Most of BioLife Solutions' fundamental indicators, such as Cash And Equivalents, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, BioLife Solutions is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

BioLife Cash And Equivalents Driver Correlations

Understanding the fundamental principles of building solid financial models for BioLife Solutions is extremely important. It helps to project a fair market value of BioLife Stock properly, considering its historical fundamentals such as Cash And Equivalents. Since BioLife Solutions' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of BioLife Solutions' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of BioLife Solutions' interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Total Liab	Total Current Assets	Accounts Payable	Net Receivables	Short Term Investments	Short Term Debt	Common Stock	Current Deferred Revenue	Intangible Assets	Property Plant Equipment	Long Term Debt	Net Tangible Assets	Capital Surpluse	Deferred Long Term Liab	Accumulated Depreciation	Long Term Debt Total	Long Term Investments	Short Long Term Debt	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		0.59	-0.15	-0.79	0.96	0.96	0.93	0.94	0.61	0.79	0.32	0.8	0.72	0.97	0.63	0.99	0.94	0.88	-0.57	-0.51	0.7	0.28	0.98	0.9	0.97
Total Stockholder Equity	0.59		-0.46	-0.38	0.46	0.53	0.34	0.3	-0.19	0.52	0.14	0.65	0.63	0.59	0.06	0.64	0.61	0.58	-0.36	-0.55	0.29	0.33	0.55	0.48	0.53
Net Debt	-0.15	-0.46		-0.23	0.09	-0.27	-0.04	0.06	0.3	0.28	0.14	-0.57	-0.47	-0.04	0.53	-0.14	-0.26	-0.2	0.39	-0.22	-0.34	0.49	-0.19	-0.4	-0.11
Retained Earnings	-0.79	-0.38	-0.23		-0.87	-0.8	-0.64	-0.79	-0.75	-0.93	-0.26	-0.59	-0.19	-0.89	-0.79	-0.82	-0.85	-0.79	0.52	0.77	-0.63	-0.63	-0.71	-0.69	-0.83
Total Liab	0.96	0.46	0.09	-0.87		0.92	0.9	0.95	0.71	0.88	0.41	0.68	0.55	0.97	0.82	0.96	0.9	0.83	-0.44	-0.59	0.66	0.44	0.93	0.84	0.96
Total Current Assets	0.96	0.53	-0.27	-0.8	0.92		0.86	0.91	0.67	0.74	0.29	0.87	0.61	0.95	0.59	0.96	0.98	0.89	-0.64	-0.51	0.82	0.24	0.94	0.97	0.96
Accounts Payable	0.93	0.34	-0.04	-0.64	0.9	0.86		0.96	0.67	0.63	0.3	0.66	0.76	0.85	0.61	0.88	0.79	0.76	-0.52	-0.25	0.61	0.06	0.94	0.82	0.89
Net Receivables	0.94	0.3	0.06	-0.79	0.95	0.91	0.96		0.8	0.73	0.31	0.66	0.59	0.91	0.73	0.91	0.86	0.81	-0.52	-0.41	0.7	0.23	0.93	0.85	0.93
Short Term Investments	0.61	-0.19	0.3	-0.75	0.71	0.67	0.67	0.8		0.58	0.18	0.38	0.07	0.65	0.72	0.58	0.62	0.58	-0.4	-0.33	0.65	0.24	0.58	0.62	0.66
Short Term Debt	0.79	0.52	0.28	-0.93	0.88	0.74	0.63	0.73	0.58		0.33	0.53	0.27	0.89	0.81	0.84	0.78	0.68	-0.31	-0.83	0.49	0.78	0.71	0.6	0.81
Common Stock	0.32	0.14	0.14	-0.26	0.41	0.29	0.3	0.31	0.18	0.33		-0.08	0.19	0.33	0.52	0.32	0.25	0.26	0.26	-0.16	0.21	0.22	0.34	0.3	0.35
Current Deferred Revenue	0.8	0.65	-0.57	-0.59	0.68	0.87	0.66	0.66	0.38	0.53	-0.08		0.62	0.78	0.23	0.81	0.88	0.8	-0.73	-0.39	0.67	0.09	0.79	0.88	0.8
Intangible Assets	0.72	0.63	-0.47	-0.19	0.55	0.61	0.76	0.59	0.07	0.27	0.19	0.62		0.56	0.1	0.67	0.55	0.53	-0.44	0.0	0.41	-0.24	0.77	0.62	0.61
Property Plant Equipment	0.97	0.59	-0.04	-0.89	0.97	0.95	0.85	0.91	0.65	0.89	0.33	0.78	0.56		0.71	0.98	0.96	0.88	-0.53	-0.67	0.69	0.47	0.93	0.87	0.97
Long Term Debt	0.63	0.06	0.53	-0.79	0.82	0.59	0.61	0.73	0.72	0.81	0.52	0.23	0.1	0.71		0.64	0.56	0.52	-0.06	-0.56	0.45	0.6	0.59	0.5	0.68
Net Tangible Assets	0.99	0.64	-0.14	-0.82	0.96	0.96	0.88	0.91	0.58	0.84	0.32	0.81	0.67	0.98	0.64		0.95	0.84	-0.54	-0.6	0.7	0.39	0.96	0.89	0.97
Capital Surpluse	0.94	0.61	-0.26	-0.85	0.9	0.98	0.79	0.86	0.62	0.78	0.25	0.88	0.55	0.96	0.56	0.95		0.94	-0.67	-0.61	0.78	0.33	0.9	0.94	0.95
Deferred Long Term Liab	0.88	0.58	-0.2	-0.79	0.83	0.89	0.76	0.81	0.58	0.68	0.26	0.8	0.53	0.88	0.52	0.84	0.94		-0.63	-0.54	0.65	0.25	0.82	0.84	0.87
Accumulated Depreciation	-0.57	-0.36	0.39	0.52	-0.44	-0.64	-0.52	-0.52	-0.4	-0.31	0.26	-0.73	-0.44	-0.53	-0.06	-0.54	-0.67	-0.63		0.23	-0.58	0.18	-0.54	-0.61	-0.53
Long Term Debt Total	-0.51	-0.55	-0.22	0.77	-0.59	-0.51	-0.25	-0.41	-0.33	-0.83	-0.16	-0.39	0.0	-0.67	-0.56	-0.6	-0.61	-0.54	0.23		-0.32	-0.83	-0.36	-0.35	-0.5
Long Term Investments	0.7	0.29	-0.34	-0.63	0.66	0.82	0.61	0.7	0.65	0.49	0.21	0.67	0.41	0.69	0.45	0.7	0.78	0.65	-0.58	-0.32		0.08	0.71	0.86	0.73
Short Long Term Debt	0.28	0.33	0.49	-0.63	0.44	0.24	0.06	0.23	0.24	0.78	0.22	0.09	-0.24	0.47	0.6	0.39	0.33	0.25	0.18	-0.83	0.08		0.19	0.1	0.34
Net Invested Capital	0.98	0.55	-0.19	-0.71	0.93	0.94	0.94	0.93	0.58	0.71	0.34	0.79	0.77	0.93	0.59	0.96	0.9	0.82	-0.54	-0.36	0.71	0.19		0.91	0.97
Net Working Capital	0.9	0.48	-0.4	-0.69	0.84	0.97	0.82	0.85	0.62	0.6	0.3	0.88	0.62	0.87	0.5	0.89	0.94	0.84	-0.61	-0.35	0.86	0.1	0.91		0.92
Capital Stock	0.97	0.53	-0.11	-0.83	0.96	0.96	0.89	0.93	0.66	0.81	0.35	0.8	0.61	0.97	0.68	0.97	0.95	0.87	-0.53	-0.5	0.73	0.34	0.97	0.92

Click cells to compare fundamentals

Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).

Competition

Predict BioLife Solutions

BioLife Cash And Cash Equivalents Changes

Cash And Cash Equivalents Changes

101.44 Million

At this time, BioLife Solutions' Cash And Cash Equivalents Changes is comparatively stable compared to the past year.

In accordance with the recently published financial statements, BioLife Solutions has 46.55 M in Cash And Equivalents. This is 94.33% lower than that of the Health Care Equipment & Supplies sector and 85.17% lower than that of the Health Care industry. The cash and equivalents for all United States stocks is 98.28% higher than that of the company.

BioLife Cash And Equivalents Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses BioLife Solutions' direct or indirect competition against its Cash And Equivalents to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of BioLife Solutions could also be used in its relative valuation, which is a method of valuing BioLife Solutions by comparing valuation metrics of similar companies.

BioLife Solutions is currently under evaluation in cash and equivalents category among its peers.

BioLife Solutions Current Valuation Drivers

We derive many important indicators used in calculating different scores of BioLife Solutions from analyzing BioLife Solutions' financial statements. These drivers represent accounts that assess BioLife Solutions' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of BioLife Solutions' important valuation drivers and their relationship over time.

	2019	2020	2021	2022	2023	2024 (projected)
Market Cap	314.9M	1.1B	1.4B	773.2M	710.4M	746.0M
Enterprise Value	309.8M	1.0B	1.4B	797.4M	717.7M	753.6M

BioLife Solutions ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, BioLife Solutions' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to BioLife Solutions' managers, analysts, and investors.

Environmental

Governance

Social

BioLife Fundamentals

	Return On Equity	-0.15
	Return On Asset	-0.0597
	Profit Margin	(0.31) %
	Operating Margin	(0.05) %
	Current Valuation	1.18 B
	Shares Outstanding	46.39 M
	Shares Owned By Insiders	1.93 %
	Shares Owned By Institutions	99.47 %
	Number Of Shares Shorted	3.5 M
	Price To Earning	173.59 X
	Price To Book	3.62 X
	Price To Sales	8.01 X
	Revenue	143.27 M
	Gross Profit	54.07 M
	EBITDA	(45.24 M)
	Net Income	(66.43 M)
	Cash And Equivalents	46.55 M
	Cash Per Share	1.09 X
	Total Debt	42.69 M
	Debt To Equity	0.06 %
	Current Ratio	3.55 X
	Book Value Per Share	7.04 X
	Cash Flow From Operations	(12.5 M)
	Short Ratio	13.43 X
	Earnings Per Share	(1.11) X
	Price To Earnings To Growth	65.38 X
	Target Price	29.8
	Number Of Employees	409
	Beta	1.88
	Market Capitalization	1.18 B
	Total Asset	412.71 M
	Retained Earnings	(313.34 M)
	Working Capital	78.43 M
	Current Asset	6.97 M
	Current Liabilities	1.73 M
	Net Asset	412.71 M

About BioLife Solutions Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze BioLife Solutions's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of BioLife Solutions using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of BioLife Solutions based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for BioLife Stock Analysis

When running BioLife Solutions' price analysis, check to measure BioLife Solutions' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioLife Solutions is operating at the current time. Most of BioLife Solutions' value examination focuses on studying past and present price action to predict the probability of BioLife Solutions' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioLife Solutions' price. Additionally, you may evaluate how the addition of BioLife Solutions to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC